Georgia’s competition regulator has fined a regional hospital operator GEL 8,000 for ignoring a market data request, twice.
That is roughly $2,950 in Georgia’s lari currency. The Georgian Competition and Consumer Agency (GCCA), the country’s antitrust and consumer protection watchdog, says LLC Imermedi, which runs the Imereti Regional Medical Center under the brand Terjolamedi, never answered.
The fine is small change next to what the GCCA has extracted from pharmaceutical firms, parking operators and cinema ticket resellers over the past year. It lands inside a healthcare pricing review the agency opened as part of a wider push into Georgia’s least transparent markets.
Two Missed Deadlines Add Up to 8,000 Lari
The GCCA requested information from Imermedi as part of a monitoring initiative into the healthcare services market, meant to gauge how competitive the sector really is. Georgia Today, which first reported the fine, said the company missed the submission deadline and then ignored a follow-up request too.
The agency examined the case and issued two separate penalties. Under Georgian law, the GCCA can demand information, including confidential data, from a business once an administrative proceeding is open. Missing the first deadline carries a GEL 3,000 fine; missing an extended deadline afterward adds another GEL 5,000. Imermedi hit both marks, for a combined GEL 8,000.
That penalty structure runs on a flat scale, unrelated to revenue. The agency’s bigger tool works differently. For abuse of a dominant market position, penalties can reach fines capped at 10% of turnover for repeat offenses. The smaller fine exists so the bigger investigations have something to work with in the first place.
Rising Prices Put Hospitals Under a New Kind of Scrutiny
The information request sent to Imermedi did not happen in isolation. Georgia’s medical services market has been under formal GCCA monitoring since 2025, one of eight sectors the agency tracked that year alongside fuel, tobacco and ride-hailing apps.
Price increases were the trigger. The agency’s own head of strategic markets monitoring put it simply.
We constantly monitor strategically important markets.
That monitoring effort moved into healthcare largely because prices kept climbing, one of the main reasons the agency gave for opening the review. Irakli Lekvinadze, the GCCA’s chairman, says the sectors under permanent watch now span:
- Fuel
- Fast-moving consumer goods
- Pesticides and agrochemicals
- Tobacco
- Blueberry and hazelnut exports
- Medical services
Each market gets periodic interim reports assessing how competitive it really is. Healthcare has become one of the busier fronts.
Georgia’s Health Sector Already Has a Competition Problem
The healthcare market was not a random pick. A 2021 GCCA assessment found that doctors frequently wrote prescriptions by brand name rather than generic name, reinforcing demand for costlier medicines even after a 2022 reform required prescribing by international non-proprietary name.
A peer-reviewed study traced part of the problem to ownership. Georgia’s retail pharmacy market is concentrated, and the three largest chains own a third of outlets. Several of those chains are also tied to pharmaceutical manufacturers, hospitals and insurers under the same ownership, the kind of structure that makes brand-name prescribing hard to separate from profit.
One private facility manager interviewed for that study put the uncertainty plainly. “We continue to feel there is a lack of a long-term vision from the state,” the manager said, describing how the gap makes it difficult to plan investment.
None of that touches Imermedi directly. But it explains why a regional clinic’s silence drew a fine instead of a shrug. The agency is trying to map a market it already suspects has structural problems, and a missing data set from one provider leaves a hole in that map.
The Agency’s Fines Keep Getting Bigger
Imermedi’s GEL 8,000 penalty barely registers against the GCCA’s recent record. The agency closed four investigations in 2025, two of them ending in infringement findings against companies with far more revenue at stake.
| Case | Sector | Penalty | Reason |
|---|---|---|---|
| Imermedi (Terjolamedi) | Healthcare | GEL 8,000 | Failed twice to submit requested market data |
| Four pharmaceutical firms, including Global TBS and Concept Pharma | Pharmaceuticals | GEL 560,000 | Abuse of a dominant position; probe opened December 2023 |
| Rustavi Auto Market and Mikado Georgia | Vehicle imports and parking | GEL 848,276 | Excessive parking fees charged to importers |
| Three online ticket sellers | Cinema ticketing | Over GEL 1.6 million (about €557,800) | Restrictive agreement under competition law |
The same year, the agency approved 18 concentrations among 24,000 business combinations it reviewed, with medical services among the sectors generating the most merger activity. Where companies skip the required notification, the agency fines them too. It found breaches in nine of those eighteen cases in 2025 and applied sanctions in each.
Set against those numbers, GEL 8,000 for missing paperwork looks small. The agency does not treat it that way. New guidelines on fine calculations, part of a wider procedural overhaul flagged by competition lawyers in 2025, apply the same escalation logic whether the target is a hospital operator or a fuel importer.
Five Years of Watching Georgia’s Health Prices
The Imermedi case did not appear out of nowhere. It is the newest entry in a five-year run of GCCA attention to how Georgians pay for medical care.
- 2021: A GCCA assessment finds that physicians in Georgia frequently prescribe by brand name, feeding demand for pricier medicines over generic alternatives.
- December 2023: The agency opens a pharmaceutical market investigation at the Ministry of Healthcare’s request.
- 2025: The pharmaceutical probe concludes with fines against four firms; medical services also joins the agency’s roster of continuously monitored markets.
- July 1, 2026: The GCCA takes the helm of the International Consumer Protection and Enforcement Network (ICPEN), a body linking regulators in more than 90 countries, as it assumes the presidency for a two-year term.
- July 16, 2026: Georgia Today reports the GEL 8,000 fine against Imermedi, the healthcare monitoring push’s first publicly reported penalty for a provider that would not cooperate.
Each step built on the last one. The pharmaceutical case gave the agency a working template for pricing investigations in health markets. Its ICPEN presidency added an international stage. Imermedi shows what happens to a smaller player in that same sector that stops responding.
Who Will Run Georgia’s Competition Watchdog After 2027?
Starting in 2027, Georgia’s competition agency will lose its five-member board and answer instead to one chairman, appointed and dismissed directly by the prime minister. That structural change arrives just as the agency has grown bolder across fuel, pharmaceuticals, auto markets and now healthcare.
The agency has been on an international upswing too. It chaired competition and consumer protection discussions on behalf of Georgia at the United Nations Conference on Trade and Development in Geneva, sat on a panel at the Organisation for Economic Co-operation and Development (OECD) focused on healthcare competition challenges, and picked up a World Bank consumer-protection award in Edinburgh for its pharmaceutical sector work.
Legislative amendments passed in February 2025 stripped out the provisions guaranteeing a five-member board from 2027 onward. Competition lawyers reported that Georgia’s agency will instead be led by a chairman appointed and dismissed by the premier, a shift flagged as one of the year’s most significant governance changes.
A single chairman answerable to the prime minister makes the agency’s independence harder to judge from outside, precisely as its healthcare monitoring push gathers pace.
Georgia’s 2014 EU Association Agreement committed the country to keeping “an authority responsible and appropriately equipped for the effective enforcement of the competition laws.” That commitment now faces its most direct test since the agency’s founding.
None of that changes what Imermedi owes. Its GEL 8,000 bill is final. It lands in 2026, the 30th anniversary of Georgia’s first independent antimonopoly authority, the distant ancestor of the agency now deciding how much the country’s clinics have to tell it.
Frequently Asked Questions
What Is the Georgian Competition and Consumer Agency?
The GCCA is Georgia’s independent antitrust and consumer protection regulator, established on April 14, 2014 under the Law on Competition. Its mandate has since grown to cover anti-dumping measures, e-commerce rules, tourism and procurement dispute resolution alongside its original competition and consumer protection functions.
How Big Can a Competition Fine Get in Georgia?
For abuse of a dominant market position, Georgian law caps fines at 5% of a company’s annual turnover, rising to 10% for repeat violations. Companies that stay overdue on an agency order can also be fined up to 5% of their average daily turnover for every day the delay continues.
Does GCCA Only Investigate Big Companies?
No. Georgia requires advance written notice of any merger once the combined annual turnover of the companies involved passes GEL 20 million, a threshold set low enough to catch mid-sized deals alongside the country’s biggest conglomerates.
How Many Consumer Complaints Is GCCA Handling in 2026?
Consumer complaints have surged well beyond the healthcare case. In the first half of 2026, consumer complaints rose 112% from a year earlier, with the agency logging 1,276 applications and fining 75 traders a combined GEL 202,281, most of it tied to online shopping disputes.
